Zentalis Pharmaceuticals ... (ZNTL)
NASDAQ: ZNTL
· Real-Time Price · USD
1.49
-0.07 (-4.49%)
At close: Oct 17, 2025, 3:59 PM
1.48
-0.67%
After-hours: Oct 17, 2025, 04:11 PM EDT
Zentalis Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
Revenue | 67.42M | n/a | n/a | n/a |
Cost of Revenue | 1.29M | 1.39M | 1.43M | 544K |
Gross Profit | 67.42M | -1.39M | -1.43M | -544K |
Operating Income | -191.19M | -253.94M | -227.29M | -216.54M |
Interest Income | n/a | n/a | 2.26K | 1.31K |
Pretax Income | -165.69M | -292.91M | -221.3M | -164.56M |
Net Income | -165.84M | -292.19M | -236.81M | -158.72M |
Selling & General & Admin | 87.11M | 59.4M | 54.55M | 40.94M |
Research & Development | 167.77M | 189.59M | 172.73M | 175.6M |
Other Expenses | 3.74M | 3.56M | n/a | n/a |
Operating Expenses | 258.62M | 252.55M | 227.29M | 216.54M |
Interest Expense | n/a | n/a | 2.58M | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 258.62M | 253.94M | 227.29M | 216.54M |
Income Tax Expense | 177K | -601K | -469K | -297K |
Shares Outstanding (Basic) | 71.08M | 65.41M | 52.86M | 42.69M |
Shares Outstanding (Diluted) | 71.08M | 65.41M | 52.86M | 42.69M |
EPS (Basic) | -2.33 | -4.47 | -4.48 | -3.72 |
EPS (Diluted) | -2.33 | -4.47 | -4.48 | -3.72 |
EBITDA | -186.17M | -275.5M | -219.87M | -164.01M |
EBIT | -187.46M | -276.89M | -221.3M | -164.56M |
Depreciation & Amortization | 1.29M | 1.39M | 1.43M | 544K |
Source: Financial Modeling Prep. Financial Sources.